A Global Analysis of Cases of Mucormycosis Recorded in the European Confederation of Medical Mycology / International Society for Human and Animal Mycology (ECMM / ISHAM) Zygomyco.net Registry from 2009 to 2022
October 3, 2025Antifungal Use in Immunocompromised Children in Europe: A 12-Week Multicenter Weekly Point Prevalence Survey (CALYPSO)
October 3, 2025Abstract
Background: Candida auris (Candidozyma auris) has emerged as an important pathogen across all continents, with clonal outbreaks and hospital transmissions. Most isolates are fluconazole resistant, and variable resistance rates are reported for amphotericin B and echinocandins.Implications: The following ECOFFs and breakpoints were established for C auris: amphotericin B: ECOFF: 2 mg/L, S: ≤0.001 mg/L, R: >2 mg/L; implying that the entire wild-type distribution is susceptible, increased exposure (I) (increased dose: 5 mg/kg liposomal amphotericin B daily); anidulafungin and micafungin: ECOFFs: 0.25 mg/L, S: ≤0.25; R: >0.25; rezafungin: ECOFF: 0.125 mg/L; and flucytosine: ECOFF: 0.5 mg/L. Importantly, notable MIC variations have been reported for C auris and some agents across commercial tests. Consequently, important detailed guidance is provided on how to validate your MIC test in-house before adopting the EUCAST breakpoints for MIC interpretation. (read more)
Arendrup MC, Guinea J, Arikan-Akdagli S, Meijer EFJ, Meis JF, Buil JB, Dannaoui E, Giske CG, Lyskova P, Meletiadis J; Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. Clin Microbiol Infect. 2025 Jul 11:S1198-743X(25)00340-4. doi: https://doi.org/10.1016/j.cmi.2025.07.002